Among the RAS family members, KRAS mutations are the most common in cancer, especially in adenocarcinomas such as pancreatic adenocarcinoma (PDAC)15, and they are associated with poorer response to the conventional therapies and worse prognosis16. The gene discussed is KRAS; the disease is adenocarcinoma.